Literature DB >> 10462749

Does paraoxonase play a role in susceptibility to cardiovascular disease?

M Aviram1.   

Abstract

Human serum paraoxonase (PON1) is an esterase that is bound to high-density lipoproteins (HDLs). It can hydrolyze organophosphates and its activity is inversely related to atherosclerosis. Some studies also suggest that a relationship exists between polymorphisms of the gene that encodes paraoxonase and coronary heart disease (CHD), whereas other studies, in different populations, have not found such an association. One mechanism by which certain PON1 allozymes might protect against atherosclerosis is by inhibition of the oxidation of HDL and low-density lipoprotein (LDL). Experimental studies suggest that this protection is associated with the ability of PON1 to hydrolyze specific lipid peroxides in oxidized lipoproteins. Interventions that preserve or enhance PON1 activity, as well as manipulations of PON1 polymorphisms, might help delay the onset of CHD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462749     DOI: 10.1016/s1357-4310(99)01546-4

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  12 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

3.  Paraoxonase 1 status in the Thai population.

Authors:  Wimon Phuntuwate; Chuthamanee Suthisisang; Banhan Koanantakul; Michael I Mackness; Bharti Mackness
Journal:  J Hum Genet       Date:  2005-05-28       Impact factor: 3.172

4.  Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study.

Authors:  Hakan Söyüt; Elif Duygu Kaya; Sükrü Beydemir
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

5.  Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Hadiss Vaisi-Raygani; A Kiani; M Aminian; E Shakiba; Y Shakiba; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2011-06-17       Impact factor: 2.316

6.  Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease.

Authors:  Asad Vaisi-Raygani; Hori Ghaneialvar; Zohreh Rahimi; Haidar Tavilani; Tayebeh Pourmotabbed; Ebrahim Shakiba; Aliakbar Vaisi-Raygani; Amir Kiani; Mahdi Aminian; Reza Alibakhshi; Cynthia Bartels
Journal:  Mol Biol Rep       Date:  2011-04-05       Impact factor: 2.316

Review 7.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

8.  The relationship between metabolic presbycusis and serum paraoxonase/arylesterase activity.

Authors:  Erol Keleş; Zeliha Kapusuz; Mehmet Ferit Gürsu; Turgut Karlıdag; Irfan Kaygusuz; Funda Gülcü Bulmuş; Sinasi Yalcın
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-20

9.  Imbalance in superoxide dismutase/thioredoxin reductase activities in hypercholesterolemic subjects: relationship with low density lipoprotein oxidation.

Authors:  Paula Rossini Augusti; Amanda Roggia Ruviaro; Andréia Quatrin; Sabrina Somacal; Greicy Michelle Marafiga Conterato; Juliana Tanara Vicentini; Marta Medeiros Frescura Duarte; Tatiana Emanuelli
Journal:  Lipids Health Dis       Date:  2012-06-21       Impact factor: 3.876

10.  Paraoxonase 1 in chronic kidney failure.

Authors:  Alejandro Gugliucci; Kazuhiko Kotani; Satoshi Kimura
Journal:  J Lipids       Date:  2012-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.